Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28966578 | 0.88 | GPR119 (0.41) | GPR119MAPTNR1H2NR1H3SLC6A7 | |
| SCHEMBL31713817 | 0.87 | GPR119 (0.44) | GPR119MAPTPTPN11 | |
| SCHEMBL31713438 | 0.85 | JAK3 (0.47) | GPR119MAPT | |
| SCHEMBL31368853 | 0.82 | OGA (0.41) | GPR119MAPTSLC6A7 | |
| SCHEMBL5467171 | 0.79 | GPR119 (0.65) | GPR119MAPTPTPN11 | |
| SCHEMBL23561131 | 0.79 | NR1H2 (0.42) | GPR119MAPTNTRK1NR1H2NR1H3 | |
| SCHEMBL27008031 | 0.78 | MAP4K4 (0.37) | GPR119MAPTNTRK1NR1H2NR1H3 | |
| SCHEMBL18096275 | 0.78 | NR1H2 (0.43) | GPR119MAPTNR1H2NR1H3 | |
| SCHEMBL23742218 | 0.78 | GPR119 (0.60) | GPR119MAPTPTPN11 | |
| SCHEMBL25187823 | 0.78 | NR1H2 (0.40) | GPR119MAPTNTRK1F2RL1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | GPR119 138/4885MAPT 2267/4885NTRK1 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.